The Metformin Active Surveillance Trial (MAST) Study

Official Title

A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin in Reducing Progression Among Men on Expectant Management for Low Risk Prostate Cancer: The MAST (Metformin Active Surveillance Trial) Study

Summary:

This study aims to see if metformin can delay the time to progression in men with low risk prostate cancer when compared to a placebo.

Trial Description

Primary Outcome:

• Time to progression

• Time to primary therapy for prostate cancer
• Time to pathological progression
• Change from baseline in disease-related patient anxiety
• Change from baseline in decisional satisfaction and decisional conflict
• Change from baseline in prostate cancer diagnosis at repeat biopsy
• Change in Gleason Score at repeat biopsy
• Change in clinical stage of prostate cancer based on digital rectal examination
• Assess the prognostic and predictive value of prostate cancer biomarkers
• To determine the safety and incidence of (serious) adverse events from the administration of 36 months of metformin to men with early stage prostate cancer

View this trial on ClinicalTrials.gov